THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 2, 2006--Amgen
(Nasdaq:AMGN), the world´s largest biotechnology company, today
announced that it expects to invest $1 billion over the next four
years to expand its manufacturing capacity in Puerto Rico to meet
rising global demand for the company´s products.
Fabrizio Bonanni, senior vice president, Manufacturing, said the
investment will include expansion of existing facilities in the
company´s manufacturing complex in Juncos, Puerto Rico, and the
construction of a new formulation, fill and finish facility. Amgen
expects to add approximately 500 staff members in Puerto Rico by 2010.
"By significantly increasing capacity in Puerto Rico and elsewhere
around the world, Amgen enhances its ability to supply every patient,
every time, with our vital medicines," said Bonanni. "We also position
ourselves to deliver on Amgen´s rich and diverse pipeline."
Bonanni said Puerto Rico´s attractive business climate and strong
commitment to developing biotechnology manufacturing capability, as
demonstrated by the formation of the Puerto Rico Science and
Technology Trust and establishment of biotechnology manufacturing
programs at University of Puerto Rico Mayaguez and elsewhere, were key
factors in the decision to expand operations there.
In Puerto Rico Amgen expects to enlarge its NEUPOGEN(R)
(Filgrastim) and Neulasta(R) (pegfilgrastim) bulk protein
manufacturing facility, licensed in 2005, as well as the newly built
EPOGEN(R) (Epoetin alfa) and Aranesp(R) (darbepoetin alfa) bulk plant.
In addition, the company anticipates construction of a new
formulation, fill and finish facility as well as upgrades to its
existing formulation, fill and finish operations.
Since Amgen´s founding in 1980, Amgen has been a pioneer in
biologics manufacturing, developing some of the first and most
successful processes for large-scale protein production. Over the last
five years, Amgen has invested more than $3 billion to enhance its
manufacturing capabilities in the United States and has added more
than 4,000 operations jobs in the U.S. since 2001.
In 2005 Amgen opened an Enbrel(R) (etanercept) plant in Rhode
Island, and announced plans to acquire Abgenix, Inc., a leading
biopharmaceutical company with a large manufacturing plant in Fremont,
Last week Amgen announced plans to invest approximately $1 billion
in new bulk protein manufacturing and formulation, fill and finish
facilities in Cork, Ireland, that will give the company capacity
closer to the patients it serves in Europe. Amgen also announced that
it intends to expand its existing research and development operations
in Cambridge, Mass., South San Francisco, Seattle, and Cambridge,
U.K., and build a new development center in Uxbridge, U.K.
Amgen´s growth in research and development marks a unique
transformation in the company´s history. As others in the industry
consolidate and reduce workforces, Amgen is launching a major global
expansion of its R&D efforts in a number of scientific hubs throughout
"This significant, long-term investment in our global R&D
infrastructure underscores the commitment of Amgen to be the world´s
best human therapeutics company," said Roger M. Perlmutter, executive
vice president, Research and Development. "In particular, our growth
in clinical development in South San Francisco and Uxbridge, U.K. will
provide the capability to deliver on the promise of our extraordinary
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below
and others that can be found in our Form 10-K for the year ended
December 31, 2004, and in our periodic reports on Form 10-Q and Form
8-K. Amgen is providing this information as of the date of this news
release and does not undertake any obligation to update any
forward-looking statements contained in this document as a result of
new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. The company´s results may
be affected by our ability to successfully market both new and
existing products domestically and internationally, sales growth of
recently launched products, difficulties or delays in manufacturing
our products, and regulatory developments (domestic or foreign)
involving current and future products and manufacturing facilities. In
addition, sales of our products are affected by reimbursement policies
imposed by first party payors, including governments, private
insurance plans and managed care providers, and may be affected by
domestic and international trends toward managed care and healthcare
cost containment as well as possible U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government regulations and
reimbursement policies may affect the development, usage and pricing
of our products. Furthermore, our research, testing, pricing,
marketing and other operations are subject to extensive regulation by
domestic and foreign government regulatory authorities. We, or others,
could identify side effects or manufacturing problems with our
products after they are on the market. In addition, we compete with
other companies with respect to some of our marketed products as well
as for the discovery and development of new products. Discovery or
identification of new product candidates cannot be guaranteed and
movement from concept to product is uncertain; consequently, there can
be no guarantee that any particular product candidate will be
successful and become a commercial product. In addition, while we
routinely obtain patents for our products and technology, the
protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors. Further,
some raw materials, medical devices, and component parts for our
product are supplied by sole third party suppliers.
EDITOR´S NOTE: An electronic version of this news release may be
accessed via our Web site at www.amgen.com. Journalists and media
representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in
the Media section of the Web site.
CONTACT: Amgen, Thousand Oaks
Mary Klem, 805-447-4587 (media)
Miguel Pereira, 787-656-1269 (Puerto Rico media)
Arvind Sood, 805-447-1060 (investors)